Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

摘要: Because lung cancer is a major health care problem in Canada, it would be useful to identify the direct costs of diagnosing and treating this disease create an analytic framework within which diagnostic therapeutic options can assessed. This paper describes method modelling for cancer. The perspective costing model that government as payer universal system. Clinical algorithms were developed describe management non-small cell (NSCLC) small (SCLC) Patients allocated treatment model, based on knowledge stage distribution cases provincial registries estimate use modalities, according experts. A microsimulation (POHEM) at Statistics Canada was used integrate data risk factors, onset progression, resource utilization medical costs. incorporates survival patients, type stage, published studies. Relapse terminal assigned during year death, order determine cost continuing cumulative over time. surviving five years assumed cured. estimates total provide 15,624 diagnosed 1988 excess $328 million. Over 82% spent first tests, therapy (surgery, chemotherapy, radiation therapy, or combinations these), hospitalization follow-up average per case $21,000, ranged from high $29,860 limited SCLC, low $16,500 Stage IV NSCLC. actual providing care, including complications, unknown our should regarded idealized management. However, POHEM has level sophistication which, we believe, reasonably reflects by modality Canada.